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Title: Identification of patients with atrial fibrillation in UK community 1 
pharmacy: an evaluation of a new service. 2 
 3 
Introduction 4 
Atrial fibrillation (AF) is an arrhythmia that affects approximately 1-2% of the 5 
population and can lead to an increased risk of stroke and circulatory failure (1). 6 
Appropriately diagnosing and treating AF can reduce the risk of these complications, 7 
which are more costly in individuals with the condition (2). Globally, many patients 8 
are asymptomatic and diagnosed as a result of an opportunistic screening (1). With 9 
advances in technology and portability of devices, this screening can now take place 10 
in locations more convenient for patients. This approach has been trialled in hospital 11 
foyers and community pharmacies with different healthcare professionals (3, 4). It 12 
has demonstrated that opportunistic screening can prove useful at identifying 13 
patients with AF, however, no research has been conducted to date in the context of 14 
the UK health system.  15 
 16 
Community pharmacy has been advocated as a potential resource for opportunistic 17 
screening and associated lifestyle interventions (5). Research has previously 18 
demonstrated the ability of pharmacies to screen patients and identify those at risk of 19 
developing other conditions, such as diabetes and cardiovascular disease (6, 7). 20 
However, a limitation of previous studies is the lack of appropriate follow-up of 21 
referred patients and a description of the collateral benefits of the screening 22 
programme in terms of further interventions provided by the pharmacist, particularly 23 
to those patients not identified as being at risk of the condition.  24 
 25 
 26 
Aim of the study 27 
The objective of this evaluation is to describe the outcomes from an AF service in UK 28 
community pharmacies in terms of referral outcomes and further interventions 29 
provided to those patients identified not at risk. 30 
 31 
Ethical approval 32 
Approval for this service evaluation was obtained from the University East Anglia 33 
(UEA) Faculty of Medicine and Health. Anonymised data were provided to the 34 
evaluation team (MT) after service completion. No additional data were collected 35 
from patients other than that required for service provision. 36 
 37 
Method 38 
The service was delivered for four months (October 2014 to January 2015) in six 39 
independent pharmacies, with a private consultation area, in the Dartford, 40 
Gravesham and Swanley area of Kent, UK. Pharmacists received face-to-face 41 
training which included knowledge of the condition, service delivery information and 42 
how to use the equipment correctly (Microlife Watch BP Office Afib monitor and 43 
AliveCor Heart Monitor). In addition, they completed a distance learning package on 44 
the management of AF in primary care.  45 
 46 
Posters and leaflets were produced to allow in-pharmacy marketing of the service so 47 
that patients could self-refer to the service. Additionally, patients were signposted to 48 
this service from others offered in the pharmacy such as smoking cessation and 49 
weight loss. Pre-booking appointments was not necessary. Recruitment to the 50 
service was by a member of the pharmacy team who identified whether patients met 51 
the following eligibility criteria: 52 
 53 
 aged 65 or over or; 54 
 aged 50-64 and diagnosed with one or more of the following conditions: 55 
o Hypertension 56 
o Heart failure 57 
o Raised cholesterol 58 
o Pulmonary embolism 59 
o Asthma/COPD 60 
o Diabetes or; 61 
 aged 50-64 and have 2 or more lifestyle risk factors: 62 
o High consumption of alcohol 63 
o Smoker 64 
o BMI > 25kg/m2 65 
 66 
Eligibility was assessed by asking patients to complete a short questionnaire to 67 
ascertain the information above, and from pharmacy medication records, where 68 
appropriate. Patients already diagnosed with AF were excluded from the service.  69 
 70 
Pharmacy team members then explained the service to eligible patients and 71 
gained their consent to participate. The service provided patients with a 72 
consultation which gathered information about their lifestyle (including alcohol 73 
intake) and current medical conditions and screened them for the condition. 74 
The Audit-C questionnaire (8) was used to assess alcohol consumption. This 75 
is a three-statement questionnaire that assesses the potential risk of a 76 
person’s drinking habits. A score of greater than five indicates harmful 77 
drinking. Patients were then screened for AF and had their blood pressure 78 
measured using a Microlife WatchBP Office Afib monitor (recommended by 79 
National Institute of Health and Care Excellence (NICE) for the detection of 80 
AF whilst monitoring blood pressure (BP)). The monitor takes three 81 
simultaneous double-arm BP measurements whilst screening for AF. It has a 82 
sensitivity of 97-100% and a specificity of 89%. If the screen picks up 83 
evidence of AF, then a one-lead electrocardiogram (ECG) is conducted on the 84 
patient using an AliveCor Heart Monitor. This method of testing has been 85 
reported in more detail elsewhere in the literature (3, 4). Both of these 86 
measurements were conducted by pharmacy team members including the 87 
pharmacist and other pharmacy staff. The consultation was predicted to last 88 
20-25 minutes if an ECG was conducted or 15-20 minutes if not. This length 89 
of time was also dependent on the number of other interventions provided as 90 
part of the service. Data was not collected on the actual length of the 91 
consultations.  92 
 93 
If the patient’s measurements showed evidence of AF, the pharmacist sent the ECG 94 
reading electronically to an AliveCor cardiologist, based in the UK at a private 95 
medical centre, for analysis. The cardiologist returned an electronic analysis report to 96 
the pharmacist within 24 hours. The pharmacist subsequently telephoned the patient 97 
to explain the results. If a patient was required to see their GP, the pharmacist 98 
emailed the GP surgery with a copy of the ECG reading, analysis report from the 99 
cardiologist and supplementary information from the consultation. Patients referred to 100 
the GP were followed up by their pharmacist to determine the actions as a result of 101 
the referral.  102 
 103 
Training ensured that feedback was provided in an appropriate manner, so that the 104 
patient was given a realistic assessment, but was not unnecessarily alarmed. During 105 
the consultation, all patients received advice on alcohol consumption, smoking, 106 
weight loss and hypertension, if risks were identified from the eligibility questionnaire 107 
or blood pressure results. This was conducted by either the pharmacy or a third party 108 
provider e.g. smoking cessation clinic.  109 
 110 
All information captured during the delivery of the service was recorded on a central 111 
database used routinely to track community pharmacy service delivery in the UK.  112 
 113 
Results 114 
594 eligible patients consented for the service, 87.7% white British. Table 1 shows 115 
the patient characteristics for the service.  116 
 117 
Table 1: Patient characteristics  118 
Patient characteristic N Mean (SD) 
Age 594 68.3 (8.9) 
Number of regular medicines 184 2.8 (2.1) 
BMI 594 27.8 (5.3) 
Systolic blood pressure 594 137.8 (17.9) 
Diastolic blood pressure 594 78.2 (10.9) 
Audit-C score 594 2.7 (2.7) 
  119 
Of the 594 patients screened, nine were identified as at risk of having AF and were 120 
referred to their GP. Seven patients provided information to the pharmacist on the 121 
outcome of the GP referral. Five (0.8% of total) had a diagnosis of AF (and were then 122 
prescribed medication), one with Torades de Pointes and one had not been 123 
diagnosed with any condition. 124 
 125 
The service also identified 109 (18.4%) patients who had a high blood pressure 126 
measurement and were not diagnosed with hypertension (who were subsequently 127 
referred to their GP), 176 (29.6%) patients with a BMI greater than 30, 131 (22.1%) 128 
with an Audit-C score greater than five (increased risk of drinking problems) and 59 129 
(9.9%) smokers. As a result, across the whole service, pharmacists provided 413 130 
interventions in 326 (54.9%) patients aimed at weight reduction (239 57.9%)), alcohol 131 
consumption (123 (29.8%)) and smoking cessation (51 (12.3%)). Seventy-seven 132 
(23.6%) patients received multiple interventions to address these problems.   133 
 134 
Discussion 135 
This service aimed to identify patients with AF in an accessible and opportunistic 136 
manner. The identification of nine cases out of approximately 600 screens (1.5%) 137 
indicates that this is potentially an alternate method of capturing these patients and 138 
aligns with previous identification rates explored in other settings and countries (3, 4). 139 
This aligns closely with figures comparing no screening with opportunistic and 140 
systematic screening, which indicates that an opportunistic approach may be more 141 
cost effective for identifying cases of AF (9).  However, the collateral benefits of the 142 
service should also be highlighted. These were the identification of a large number of 143 
patients with undiagnosed hypertension and those with lifestyle risk factors for other 144 
long-term conditions e.g., diabetes and COPD. At the point of identification, the 145 
pharmacist was then able to provide appropriate and established pharmacy public 146 
health interventions to address these issues. Evidence from other studies suggests 147 
that patients view the pharmacist’s involvement in public health services as good and 148 
they are satisfied with the service experience (10).  149 
 150 
This service screened a large number of patients in an opportunistic manner, whilst 151 
making full use of the pharmacy team. The limitations of the evaluation centre on the 152 
lack of follow-up of patients who received advice regarding weight reduction, alcohol 153 
consumption or smoking cessation. Similarly, patients who were identified as having 154 
high blood pressure were not followed up to determine their actions as a result of the 155 
test. Patient and pharmacist feedback on the service was also not obtained which 156 
may have been useful to understand their reactions to discovering cases of AF.   157 
 158 
Conclusion 159 
This evaluation supports previous work by Lowres and Le Page regarding 160 
opportunistic screening for AF in settings other than the clinic or GP surgery. Our 161 
work goes further than other screening service evaluations for other conditions by 162 
characterising the interventions provided to, not only those identified with the target 163 
condition - in this case AF - but those without it. This demonstrates that pharmacies 164 
can provide this type of screening service and public health interventions as part of 165 
routine practice. However, the true effect of these additional interventions, along with 166 
appropriate follow-up, should be the focus of future studies.  167 
 168 
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